

**Exhibit 1**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**(Dollars in thousands)**

	As of December 31, 2011 US\$ (Note 1)	As of December 31, 2012 US\$ (unaudited)
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	124,311	247,859
Restricted cash and restricted investment (Note 2)	—	21,528
Short-term investments	479,173	615,003
Accounts receivable, net	200,437	185,701
Inventories	94,690	110,099
Value added tax receivables	10,833	7,427
Other receivables	16,590	15,704
Prepayments and deposits	9,792	11,081
Deferred tax assets	3,483	6,443
Total current assets	<u>939,309</u>	<u>1,220,845</u>
Other assets	7,330	10,811
Accounts receivables, net, non-current	—	2,172
Advances for purchase of plant and equipment	6,239	3,009
Property, plant and equipment, net	237,952	268,010
Land use rights, net	55,272	56,921
Intangible assets, net	84,029	132,334
Goodwill	128,840	163,016
Total assets	<u>1,458,971</u>	<u>1,857,118</u>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
Current liabilities:		
Short-term bank loans	50,475	85,100
Notes payable	7,013	8,697
Accounts payable	48,501	53,244
Advances from customers	20,700	17,550
Salaries payable	38,784	69,919
Other payables	65,357	108,528
Purchase consideration payable	2,142	20,354
Income taxes payable	16,847	30,305
Other taxes payable	7,412	8,894
Total current liabilities	<u>257,231</u>	<u>402,591</u>
Long-term bank loan	35,025	50,039
Other long-term payables	2,355	4,004
Deferred tax liabilities, net	12,925	23,369
	<u>50,305</u>	<u>77,412</u>
Shareholders' equity:		
Ordinary shares	15	15
Additional paid-in capital	486,314	514,280
Retained earnings	566,184	699,992
Accumulated other comprehensive income	100,139	116,556
Treasury stock	(10,160)	—
Total shareholders' equity	<u>1,142,492</u>	<u>1,330,843</u>
Non-controlling interest	8,943	46,272
Total equity	<u>1,151,435</u>	<u>1,377,115</u>
Total liabilities and shareholders' equity	<u>1,458,971</u>	<u>1,857,118</u>

- (1) Financial information is extracted from the audited financial statements included in the Company's fiscal year 2011 20F.  
(2) Restricted cash and restricted investment are those purchase consideration in connection with our acquisition being held on escrow accounts.

**Exhibit 2**  
**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
**(Dollars in thousands, except for share and per share data)**

	Three months ended December 31,		Year ended December 31,	
	2011 US\$ (unaudited)	2012 US\$ (unaudited)	2011 US\$ (Note 1)	2012 US\$ (unaudited)
Net revenues				
- <i>PRC</i>	117,630	148,136	374,312	472,991
- <i>International</i>	146,500	167,980	506,431	587,063
Net revenues	264,130	316,116	880,743	1,060,054
Cost of revenues	(121,035)	(133,355)	(394,302)	(459,389)
Gross profit	143,095	182,761	486,441	600,665
Selling expenses	(51,917)	(53,688)	(167,049)	(188,804)
General and administrative expenses	(17,689)	(36,467)	(70,330)	(116,228)
Research and development expenses	(25,589)	(32,926)	(82,024)	(104,302)
Operating income	47,900	59,680	167,038	191,331
Other income, net	516	177	3,108	1,619
Interest income	7,258	7,949	20,816	30,794
Interest expense	(470)	(1,028)	(1,390)	(4,093)
Income before income taxes and non-controlling interests	55,204	66,778	189,572	219,651
Provision for income taxes	(8,220)	(9,895)	(22,647)	(37,369)
Net income	46,984	56,883	166,925	182,282
Less: Net income attributable to non-controlling interests	(189)	(1,034)	(296)	(2,073)
Net income attributable to the Company	46,795	55,849	166,629	180,209
Basic earnings per share	0.41	0.48	1.45	1.54
Diluted earnings per share	0.40	0.47	1.41	1.50
Shares used in the computation of:				
Basic earnings per share	115,466,221	117,358,594	115,254,095	116,749,213
Diluted earnings per share	118,365,008	120,099,229	118,449,851	119,815,004

(1) Financial information is extracted from the audited financial statements included in the Company's fiscal year 2011 20F.

**Exhibit 3**

**MINDRAY MEDICAL INTERNATIONAL LIMITED**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(Dollars in thousands)**

	Three months ended December 31,		Year ended December 31,	
	2011	2012	2011	2012
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(Note 1)	(unaudited)
<b>Cash flow from operating activities:</b>				
Net income	46,795	55,849	166,629	180,209
Adjustments to reconcile net income to net cash from operating activities	13,353	21,091	49,825	71,797
Changes in current assets and liabilities	36,287	67,953	(24,050)	73,660
<b>Net cash generated from operating activities</b>	<b>96,435</b>	<b>144,893</b>	<b>192,404</b>	<b>325,666</b>
<b>Cash flow from investing activities:</b>				
Acquisition cost, net of cash acquired	—	(3,064)	(6,530)	(34,552)
Capital expenditure	(26,207)	(18,361)	(89,938)	(65,605)
Increase in restricted cash and restricted investment	—	(21,528)	—	(21,528)
Proceeds from sale of short-term investments	7,150	—	100,274	144,395
Increase in short-term investments and changes in other investing activities	(70,940)	(19,727)	(262,085)	(255,255)
<b>Net cash used in investing activities</b>	<b>(89,997)</b>	<b>(62,680)</b>	<b>(258,279)</b>	<b>(232,545)</b>
<b>Cash flow from financing activities:</b>				
Repayment of bank loans	—	(2,475)	—	(2,475)
Proceeds from bank loans	—	—	85,399	52,000
Dividend paid	—	—	(34,522)	(46,401)
Proceeds from exercise of options	1,730	1,964	7,121	24,593
Stock repurchase	(10,160)	—	(10,160)	—
Cash contribution from non-controlling interest	—	—	797	506
<b>Net cash (used in) generated from financing activities</b>	<b>(8,430)</b>	<b>(511)</b>	<b>48,635</b>	<b>28,223</b>
<b>Net (decrease) increase in cash and cash equivalents</b>	<b>(1,992)</b>	<b>81,702</b>	<b>(17,240)</b>	<b>121,344</b>
Cash and cash equivalents at beginning of period	124,785	164,499	137,502	124,311
Effect of exchange rate changes on cash	1,518	1,658	4,049	2,204
Cash and cash equivalents at end of period	<b>124,311</b>	<b>247,859</b>	<b>124,311</b>	<b>247,859</b>

(1) Financial information is extracted from the audited financial statements included in the Company's fiscal year 2011 20F.

**Exhibit 4**
**MINDRAY MEDICAL INTERNATIONAL LIMITED  
RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE  
NEAREST COMPARABLE GAAP MEASURES  
(Dollars in thousands, except for share and per share data)**

	Three months ended December 31,		Year ended December 31,	
	2011 (unaudited) US\$	2012 (unaudited) US\$	2011 (unaudited) US\$	2012 (unaudited) US\$
<b>Non-GAAP net income</b>	51,797	61,658	186,325	211,687
<i>Non-GAAP net margin</i>	19.6%	19.5%	21.2%	20.0%
Amortization of acquired intangible assets	(1,931)	(3,404)	(7,255)	(8,298)
Deferred tax impact related to acquired intangible assets	87	327	189	504
Dispute related legal fees	—	—	(262)	—
Dispute charges	—	—	—	(9,700)
Share-based compensation	(3,158)	(2,732)	(12,368)	(13,984)
GAAP net income	46,795	55,849	166,629	180,209
<i>GAAP net margin</i>	17.7%	17.7%	18.9%	17.0%
Non-GAAP basic earnings per share	0.45	0.53	1.62	1.81
Non-GAAP diluted earnings per share	0.44	0.51	1.57	1.77
GAAP basic earnings per share	0.41	0.48	1.45	1.54
GAAP diluted earnings per share	0.40	0.47	1.41	1.50
Shares used in computation of:				
Basic earnings per share	115,466,221	117,358,594	115,254,095	116,749,213
Diluted earnings per share	118,365,008	120,099,229	118,449,851	119,815,004
<b>Non-GAAP operating income</b>	52,989	65,816	186,923	223,313
<i>Non-GAAP operating margin</i>	20.1%	20.8%	21.2%	21.1%
Amortization of acquired intangible assets	(1,931)	(3,404)	(7,255)	(8,298)
Dispute related legal fees	—	—	(262)	—
Dispute charges	—	—	—	(9,700)
Share-based compensation	(3,158)	(2,732)	(12,368)	(13,984)
GAAP operating income	47,900	59,680	167,038	191,331
<i>GAAP operating margin</i>	18.1%	18.9%	19.0%	18.0%
<b>Non-GAAP gross profit</b>	144,503	184,799	491,870	606,214
<i>Non-GAAP gross margin</i>	54.7%	58.5%	55.8%	57.2%
Amortization of acquired intangible assets	(1,219)	(1,849)	(4,667)	(4,738)
Share-based compensation	(189)	(189)	(762)	(811)
GAAP gross profit	143,095	182,761	486,441	600,665
<i>GAAP gross margin</i>	54.2%	57.8%	55.2%	56.7%
<b>Non-GAAP selling expenses</b>	(50,249)	(51,165)	(160,032)	(180,788)
<i>Non-GAAP as % of total revenues</i>	19.0%	16.2%	18.2%	17.1%
Amortization of acquired intangible assets	(712)	(1,555)	(2,588)	(3,560)
Share-based compensation	(956)	(968)	(4,429)	(4,456)
GAAP selling expenses	(51,917)	(53,688)	(167,049)	(188,804)
<i>GAAP as % of total revenues</i>	19.7%	17.0%	19.0%	17.8%
<b>Non-GAAP general and administrative expenses</b>	(16,734)	(35,966)	(66,950)	(102,119)
<i>Non-GAAP as % of total revenues</i>	6.3%	11.4%	7.6%	9.6%
Dispute related legal fees	—	—	(262)	—
Dispute charges	—	—	—	(9,700)
Share-based compensation	(955)	(501)	(3,118)	(4,409)
GAAP general and administrative expenses	(17,689)	(36,467)	(70,330)	(116,228)
<i>GAAP as % of total revenues</i>	6.7%	11.5%	8.0%	11.0%
<b>Non-GAAP research and development expenses</b>	(24,531)	(31,852)	(77,965)	(99,995)
<i>Non-GAAP as % of total revenues</i>	9.3%	10.1%	8.9%	9.4%
Share-based compensation	(1,058)	(1,074)	(4,059)	(4,307)
GAAP research and development expenses	(25,589)	(32,926)	(82,024)	(104,302)
<i>GAAP as % of total revenues</i>	9.7%	10.4%	9.3%	9.8%

**Exhibit 5****MINDRAY MEDICAL INTERNATIONAL LIMITED  
RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES,  
DEPRECIATION AND AMORTIZATION  
(Dollars in thousands)**

	Three months ended December 31,		Year ended December 31,	
	2011	2012	2011	2012
	US\$	US\$	US\$	US\$
	(unaudited)	(unaudited)	(unaudited)	(unaudited)
GAAP net income	46,795	55,849	166,629	180,209
Interest income	(7,258)	(7,949)	(20,816)	(30,794)
Interest expense	470	1,028	1,390	4,093
Provision for income taxes	8,220	9,895	22,647	37,369
Earnings before interest and taxes ("EBIT")	48,227	58,823	169,850	190,877
Depreciation	6,367	7,445	23,216	28,043
Amortization	3,019	5,606	10,661	14,361
Earnings before interest, taxes, depreciation, and amortization ("EBITDA")	57,613	71,874	203,727	233,281